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Abstract
Transforming growth factor-K (TGF-K) is a member of the epidermal growth factor family. It activates signal transduction
pathways leading to cell proliferation through the interaction with cell surface epidermal growth factor receptor. The
overexpression of TGF-K has been found in many types of cancers and is thought to be involved in the genesis and
maintenance of these tumors. Recent results also implicate this growth factor in the development of certain diabetic
complications, such as atherosclerosis. The function of TGF-K can be tightly controlled at the level of transcription of its
gene. We have previously characterized the proximal TGF-K promoter and identified two neighboring regulatory elements
that appeared to cooperate with each other in the regulation of TGF-K transcription. The transcription factor that functions
through the distal element was identified as AP-2, a protein that was found to be induced by the oncoprotein, Ras. However,
what factor binds and controls the proximal regulatory element (PRE) is still unclear. Here, we report the purification and
preliminary characterization of the PRE-binding transcription factor TEF1 by sequence-specific DNA-affinity
chromatography from rat kidney nuclear extracts. The purified TEF1 migrates on the SDS^PAGE at a molecular mass
of about 36 kDa. It specifically interacts with the PRE and was able to strongly activate transcription from the TGF-K
promoter in HeLa cell nuclear extracts in an in vitro transcription assay. The UV cross-linking experiment confirmed that
this 36 kDa protein is indeed the protein that specifically binds the PRE. We also show that the spacing between the AP-2
and the TEF1 sites in the TGF-K promoter has little effect on the transcription from the TGF-K promoter. The purification
of TEF1 furthers our understanding of how TGF-K expression is regulated and may help us understand the upstream
signaling events that lead to the elevated expression of this growth factor. ß 1999 Elsevier Science B.V. All rights reserved.
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1. Introduction
Transforming growth factor-K (TGF-K) is a poly-
peptide mitogen highly homologous to the epidermal
growth factor (EGF) [1]. TGF-K is synthesized as a
160-amino-acid transmembrane precursor from
which the 50-amino-acid mature peptide is released
[2]. Both the membrane anchored and soluble forms
are biologically active through interaction with cell
surface EGF receptors.
TGF-K was ¢rst discovered in the media of retro-
virally-transformed ¢broblasts [3,4]. It appears to
play an important role in oncogenesis. The elevated
expression of TGF-K has been found in many types
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of tumors such as mammary, squamous, and renal
carcinomas, melanomas, hepatomas, and glioblasto-
mas [5^7]. When transfected with a TGF-K expres-
sion vector, certain cell lines became transformed
[8^10]. Also, transgenic mice overexpressing TGF-K
often develop neoplastic lesions in the tissues to
which TGF-K overexpression has been directed
[11^14]. The fact that many tumor cells coexpress
TGF-K and the EGF receptor suggests an autocrine
mechanism of growth stimulation by TGF-K [15].
TGF-K is also a potent inducer of angiogenesis in
vivo [16] that also provides growth advantages to
tumor cells.
Besides its role in the genesis and maintenance of
tumors, recent results also imply that TGF-K may be
involved in the development of certain diabetic com-
plications, such as atherosclerosis. TGF-K expression
has been localized to the vascular smooth muscle
cells in the arterioles [17], suggesting its involvement
in the growth regulation of these cells. In rat aortic
smooth muscle cells, exposure to glucosamine or to
superphysiological concentrations of glucose can up-
regulate the transcription of this gene [18]. We spec-
ulate that the modi¢cation of proteins, probably
transcription factors, by glucose-induced glycosyla-
tion stimulated TGF-K expression which leads to
the overproliferation of the blood vessel cells.
The function of TGF-K is tightly controlled by the
regulation of its gene transcription. The TGF-K pro-
moter regulates expression of its gene through devel-
opment [19] and mediates changes induced by DNA
methylation [20], hormones [21^25], and high glucose
concentrations [18]. The promoters of the human
and rat TGF-K genes have been cloned [25^27]. Their
most characteristic features are the apparent lack of
TATA and CCAAT sequences [26] and high GC
contents. Elements in the human and rat TGF-K
promoters have been partially characterized. The hu-
man core promoter contains a nonconsensus TATA
box that is recognized by TATA-binding protein
(TBP) [28] and an initiator element that accurately
orients the transcription complex, giving rise to a
unique transcription initiation site [29]. In addition,
Sp1 (human and rat) and p53 (human) play roles as
transcriptional enhancers for the TGF-K promoter
[20,28,30]. In our recent characterization of the prox-
imal human TGF-K promoter, we also identi¢ed a
regulatory element for transcription factor AP-2 [31].
Another group, in the meantime, showed that the
AP-2 site also exists in the rat TGF-K promoter
and is functionally important in regulating TGF-K
expression [32]. This functional conservation among
di¡erent species suggests the involvement of AP-2 in
many important biological functions that are tightly
controlled by TGF-K. AP-2 has also been shown to
play a role in the function of the oncoprotein Ras.
The expression of AP-2 is stimulated by Ras trans-
formation [33] in PA-1 cells. Interestingly, TGF-K
expression is also increased in cells transformed by
Ras, suggesting a possible role for AP-2 in the Ras
induction of TGF-K [34]. A neighboring element
downstream from the AP-2 site in the TGF-K pro-
moter, termed the proximal regulatory element
(PRE), is also essential for the maximal expression
of TGF-K in human mammary carcinoma MDA468
cells [31], cervical cancer HeLa cells, and human hep-
atoma HepG2 cells (our unpublished data). PRE ap-
pears to act cooperatively with the AP-2 element in
regulating TGF-K transcription [31]. DNA^protein
interaction studies provided evidence that nuclear
protein from MDA468 cells binds speci¢cally to
this element [31]. However, we could not ¢nd a
match to the consensus binding sites for known tran-
scription factors within this element.
In this study, we describe the puri¢cation and pre-
liminary characterization of the transcription factor
that speci¢cally interacts with the PRE. This factor,
termed TEF1, was puri¢ed from rat kidney cells to
essential purity by sequence-speci¢c DNA-a⁄nity
chromatography. The puri¢ed TEF1 was able to ac-
tivate transcription from the TGF-K promoter in an
in vitro transcription assay. The isolation of the
TEF1 may contribute to our understanding of how
TGF-K expression is regulated during carcinogenesis
and, perhaps, during the development of diabetic
atherosclerosis.
2. Materials and methods
2.1. Preparation of rat kidney nuclear extracts
We used a method for nuclear extract preparation
modi¢ed from Andrews and Faller [35]. Rat kidneys
were removed and cut into small pieces in cold phos-
phate-bu¡ered saline (PBS). After rinsing, the tissues
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were homogenized in 8 volumes of bu¡er A (10 mM
Tris^HCl (pH 8.0), 10 mM NaCl, 3 mM MgCl2,
0.5% NP-40) in a Brinkmann homogenizer (Poly-
tron) with 6 strokes up and down at 1000 rpm.
The homogenates were immediately centrifuged at
2200 rpm, 4‡C, for 15 min. The pellet was washed
in the same bu¡er but contained no NP-40 for sev-
eral times until the white ¢nal nuclei pellet was ob-
tained. The nuclei was resuspended in 2 volumes of
bu¡er B (20 mM Hepes (pH 7.9), 20% glycerol,
1.5 mM MgCl2, 0.2 mM EDTA, 0.4 mM NaCl,
1 mM DTT, 1 mM PMSF, 1 Wg/ml each of pepstatin
A, leupeptin, and aprotinin) and incubated at 4‡C
for 30 min with occasional mixing. Nuclear extracts
were obtained by centrifuging at 14 000 rpm, 4‡C, in
a microcentrifuge and collecting the supernatant. The
existence of the interested DNA-binding protein in
the preparation was veri¢ed by gel mobility shift as-
says using the PRE probe.
2.2. Puri¢cation of TEF1
Preliminary puri¢cation of nuclear extracts was
performed before they were loaded onto the DNA
a⁄nity column. Rat kidney nuclear extracts were
diluted with bu¡er Z (25 mM Hepes (pH 7.6),
12.5 mM MgCl2, 1 mM DTT, 20% glycerol, 0.1%
NP-40) to adjust the ¢nal concentration of KCl to
0.1 M, and loaded onto a 5 ml Econo-Pac heparin
column (Bio-Rad Laboratories). The proteins were
step eluted with bu¡er Z containing increasing
amounts of KCl (0.2 M to 1.0 M with 0.1-M inter-
vals). Most PRE-binding activities were eluted in the
0.4 M, 0.5 M, and 0.6 M KCl fractions. These frac-
tions were pooled, diluted with bu¡er Z to give a
¢nal KCl concentration of 0.18 M, and then loaded
onto a wheat germ lectin agarose column. The col-
umn was washed extensively with bu¡er Z (0.1 M
KCl) before the bound protein was eluted consecu-
tively with the same bu¡er containing 0.3 M and
0.5 M N-acetylglucosamine. The PRE-binding activ-
ity remained predominantly in the £ow-through frac-
tion. This fraction was diluted with bu¡er Z to give
the KCl concentration of 0.1 M and was loaded onto
a 1 ml DNA a⁄nity column (50^60 Wg/ml DNA)
prepared by coupling multimerized PRE oligonucleo-
tide (see Section 2.3 for sequence; average length
8-mer) to CNBr-activated Sepharose 4B (Pharmacia
Biotech) essentially as described [36]. The £ow-
through was reloaded twice onto the column and
the bound protein was then eluted with 1 ml bu¡er
Z containing increasing amounts of KCl (0.2 M to
1.0 M, with 0.1-M intervals). Most PRE-binding ac-
tivity was eluted at 0.4 M and 0.5 M KCl. These two
fractions were combined, diluted with bu¡er Z (to
give a 0.1 M KCl), and incubated with nonspeci¢c
DNA fragments poly(dI^dC) and DRE at a ¢nal
concentration of 2 ng/Wl and 10 pmol/ml, respec-
tively, on ice for 30 min. The reactions were then
centrifuged and the supernatant was repuri¢ed by
the DNA column exactly as described above. All
the puri¢cation procedures were performed at 4‡C,
and the elution fractions were frozen in liquid nitro-
gen and stored at 380‡C. The DNA binding activ-
ities of the fractions from each puri¢cation step were
determined by gel mobility shift assays.
2.3. Gel mobility shift assay
Double-stranded oligonucleotide probes with 5P
overhangs were labeled with [K-32P]dCTP using the
Klenow fragment of DNA polymerase I. The binding
reactions were carried out at room temperature for
20 min in a total volume of 35^40 Wl containing
50 000^80 000 cpm (0.02 pmol) of probes, indicated
amount of protein, 20 mM Hepes (pH 7.9), 50 mM
KCl, 1 mM MgCl2, 10% glycerol, 1 mM DTT,
0.1 mg/ml BSA, and, as indicated, various amounts
of the unlabeled competitor oligonucleotides. Gel
mobility shift assays using the crude rat kidney nu-
clear extract also contained 1 Wg poly(dI^dC). The
reactions were resolved on a 6% nondenaturing
acrylamide gel in 0.5U TBE bu¡er.
Oligonucleotides used in gel mobility shift assays
are as follows (only top strands are shown): PRE, 5P-
GATCCGCGCTGCGGGGCGAGTGCCAGCAG-
AGAGGCGCTCA-3P ; DRE, 5P-GATCTTCCTAT-
TTCCGCCCGGCGGGCAGCGCTGAGACGC-3P.
2.4. UV cross-linking of protein to DNA
Protein fractions were incubated with the PRE
probe as described in the procedure for gel mobility
shift assay. The binding reactions were then sub-
jected to UV irradiation (10 cm from the light source
of 254 nM) in a UV Stratalinker (Stratagene) for the
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indicated times. The reactions were then mixed with
equal volumes of the 2U sodium dodecyl sulfate
(SDS) sample bu¡er (125 mM Tris^HCl (pH 6.8),
4% SDS, 20% glycerol, 10% L-mercaptoethanol,
0.2% bromophenol blue), boiled, and resolved on
7.5% SDS^polyacrylamide gel electrophoresis
(PAGE).
2.5. In vitro transcription
Procedure for in vitro transcription was modi¢ed
from that of a transcription kit obtained from Prom-
ega. 560 ng of mixed DNA templates (280 ng each)
was incubated with 5 Wl (V12 mg/ml) HeLa nuclear
extracts (Promega) and indicated amounts of the di-
alyzed 0.4 M fraction from the DNA-a⁄nity chro-
matography in a 25 Wl reaction containing 12.5 mM
Hepes (pH 7.6), 50 mM KCl, 9 mM MgCl2, 0.4 mM
each of ATP, CTP and GTP, 16 WM of UTP, 8 WCi
of [32P]UTP, 10% glycerol, and 40 U of RNasin
(Promega). The transcription reactions were per-
formed at 30‡C for 60 min. The reactions were
then stopped by adding 175 Wl of the stop solution
(0.3 M Tris^HCl (pH 7.4), 0.3 M sodium acetate,
0.5% SDS, 2 mM EDTA, 3 Wg/ml tRNA) prewarmed
to room temperature. The samples were puri¢ed by
phenol/chloroform/isoamyl alcohol (25:24:1) extrac-
tion, precipitated by ethanol, resuspended in form-
amide dyes, boiled for 10 min and loaded onto a 6%
sequencing gel.
Wild-type or mutant TGF-K promoter constructs
used as DNA templates in the in vitro transcription
experiments (pGL3181/+38, pGL-M389/396, pGL-
M3121/3128) were described previously [31]. These
plasmids were linearized by KpnI and Bsu36I. An
adenovirus major late promoter (AdMLP) construct,
pGAM, linearized by XbaI, was also included in each
reaction as an internal control for transcription e⁄-
ciency.
2.6. Plasmids
Plasmids containing various spacings between the
DRE and the PRE sites were constructed as follows.
A 16 bp double-stranded oligonucleotide £anked by
XhoI and SalI sites at the 5P- and 3P-ends, respec-
tively, was kinased and self-ligated. Multimerized oli-
gonucleotides of various lengths were puri¢ed by
agarose gel electrophoresis and were ligated into
the unique XhoI site between the DRE and the
PRE sites of the TGF-K promoter in pM3104/
3111 [31]. The sequence of the top strand oligonu-
cleotide was 5P-TCGAGGATCTAGATCG-3P. To
make deletion mutant of the spacing element,
pM3104/3111 was digested with XhoI, blunt-ended
by the Klenow fragment of DNA polymerase I,
phenol/chloroform puri¢ed, and then digested with
DraIII. The smaller fragment (V600 bp) from this
digestion was puri¢ed and was ligated with the larger
fragment (V5 kb) from the DraIII plus Eco47III
digestion (Eco47III is another unique site located
between the DRE and the PRE sites) of pGL3181/
+38 [29]. The 220 bp wild-type, PREm, and control
TGF-K promoter constructs used in transient trans-
fection assays correspond to pGL3181/+38, pM389/
396, and pM3104/3111, respectively; the 1.1 kb
version of these constructs correspond to pGLT1.1,
pGLT1.1PREm, and pGLT1.1(3104m), respectively.
These plasmids were described previously [31].
2.7. Cell culture and transfection
MDA468 cells were maintained at 37‡C in a CO2
incubator in Dulbecco’s modi¢ed Eagle’s medium
supplemented with 10% newborn calf serum or 10%
fetal bovine serum. Cells were grown to con£uence,
washed with PBS, trypsinized, and resuspended in
full culture medium. Approximately 1.0U107 cells
were transfected by electroporation with a total of
30 Wg of plasmid DNA consisting of 20 Wg of the
indicated promoter^luciferase constructs and 10 Wg
of the pCMV-L-gal, a plasmid containing the CMV
promoter-driving L-galactosidase as a control for
transfection e⁄ciency [20]. Cells were harvested 24 h
after transfection and luciferase and L-galactosidase
activities were assayed as previously described [20].
3. Results
3.1. DNA a⁄nity puri¢cation of TEF1
Fig. 1 shows a schematic representation of the
proximal TGF-K promoter and the cis-acting DNA
elements that have been identi¢ed. The importance
of PRE in regulating TGF-K promoter has been
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demonstrated by transient transfection experiments
in MDA468 cells [31], HeLa cells, and normal rat
kidney (NRK) cells (our unpublished data). Nuclear
proteins from these cells have been shown to interact
speci¢cally with PRE in in vitro binding assays [31].
We prepared nuclear extracts from rat kidney cells
and used them as starting materials for TEF1 puri-
¢cation. The DNA binding activity of TEF1 in each
puri¢cation fraction was examined by gel mobility
shift assay. Crude nuclear extract was ¢rst frac-
tionated by a heparin^agarose column, from which
the majority of TEF1 activity was eluted at 0.4 M,
0.5 M, and 0.6 M KCl. These fractions were com-
bined and loaded onto a wheat germ lectin^agarose
column. The rationale for conducting this puri¢ca-
tion step is that a number of RNA polymerase II
transcription factors, including Sp1, serum response
factor, and RNA polymerase II itself, were shown to
be glycosylated [37^40], and the N-acetylglucosamine
sugar residues covalently attached to the protein are
avidly bound by the lectin germ agglutinin (WGA)
[41]. Therefore, if TEF1 is glycosylated, it can be
highly puri¢ed by eluting the bound WGA column
with high concentration of N-acetylglucosamine.
However, in our puri¢cation, the majority, if not
all, of the TEF1 activity remained in the £ow-
through, suggesting that TEF1 is not glycosylated
or is not glycosylated highly enough to be bound
by WGA. Nevertheless, TEF1 could still have been
puri¢ed to a certain degree by its separation from
other glycosylated proteins that did bind the WGA
column. The nonspeci¢c DNA-binding proteins that
still remained in the £ow-through from the WGA
column were further competed away by incubating
with nonspeci¢c competitors poly(dI^dC) and DRE.
TEF1 was then puri¢ed to homogeneity by DNA
a⁄nity column containing multimerized PRE.
The PRE sequence identi¢ed previously [31] is in-
dicated in Fig. 1. To further de¢ne the nucleotides
required for e⁄cient TEF1 binding, we synthesized
oligonucleotides containing various portions of PRE
and its £anking sequences and used them in gel shift
Fig. 1. Schematic representation of the human TGF-K pro-
moter. The proximal TGF-K promoter from 3310 to +38 is
shown, where the transcription initiation site is +1 (indicated
by an arrow). This portion of the promoter is able to confer ef-
¢cient basal transcription and responsiveness to hormones such
as phorbol ester and EGF [22^24,48]. The cis-acting elements
that have been identi¢ed in this region of the promoter are in-
dicated. TBP, TATA-binding protein; Inr, initiator; PRE, prox-
imal regulatory element. The DNA sequence of the PRE is also
shown.
Table 1
Summary of TEF1 puri¢cation
Procedure Total protein
(mg)
Total activity
(units)
Speci¢c activity
(unit/mg)
Recovery
(%)
Puri¢cation
factor
1. Nuclear extract 50 100 2 100 1
2. Heparin^agarose (0.4+0.5+0.6 M KCl) 4 50a 12.5 50 6.3
3. WGA (FT) 3.2 46 14.4 46 7.2
4. DNA a⁄nity-1 (0.4+0.5 M KCl) 0.0006 16.7 27 833 16.7 13 917
5. DNA a⁄nity-2 (0.4 M) 0.0005 15 30 000 15 15 000
Puri¢cation e⁄ciency of TEF1 was estimated. Elution fractions used in determining TEF1 recovery from each puri¢cation step are in-
dicated. FT, £ow-through. The protein fractions puri¢ed by DNA a⁄nity chromatography were visualized by SDS^polyacrylamide gel
electrophoresis followed by silver staining, and the amount of TEF1 was estimated against protein standards (data not shown). Total
activity re£ects the amount of TEF1 that binds the PRE probe as determined by gel shift assay under the conditions of DNA excess.
The total activity of the nuclear extract was arbitrarily set at 100 units. Speci¢c activity is de¢ned as the TEF1 activity per mg of total
protein. Recovery indicates the percentage of total TEF1 activity puri¢ed as compared with that of nuclear extract. Puri¢cation factor
is the -fold increase of speci¢c activity as compared with nuclear extract.
aWe did not determine the total activity of TEF1 puri¢ed by heparin^agarose chromatography and assume a 50% recovery on the ba-
sis of our parallel experiments of heparin^agarose puri¢cation of TEF1 from rat kidney nuclear extracts (data not shown).
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assays (data not shown). Our results indicate that, in
addition to the PRE sequence shown in Fig. 1, nu-
cleotides £anking this PRE element are also neces-
sary in e⁄cient TEF1 binding. While a minimal of
¢ve nucleotides 5P to the PRE and four nucleotides
3P to the PRE accounted for a detectable binding by
TEF1, the PRE element with eleven 5P nucleotides
and eight 3P nucleotides gave the strongest PRE-
TEF1 interaction while still retaining a very low level
of nonspeci¢c binding. We used this sequence in our
Fig. 2. Puri¢cation of TEF1. (A) DNA binding activity of the puri¢ed protein. Four Wl of each fraction from the ¢nal step of puri¢-
cation was tested for its binding activity to the PRE in a gel mobility shift assay, except that 5 Wl was used instead for the input (L)
and £ow-through (FT) fraction. Where indicated, a 7-fold excess of either the speci¢c (PRE) or the nonspeci¢c (DRE) competitors
was also added. The arrow indicates nonspeci¢c shift that appear in all the lanes. P, free probe. (B) SDS^PAGE of the various frac-
tions obtained during TEF1 puri¢cation. Samples (40 Wl) of the indicated fractions from the ¢nal step of TEF1 puri¢cation were elec-
trophoresed on a 10% SDS^polyacrylamide gel and silver stained. Molecular mass markers are indicated on the left.
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puri¢cation procedure and DNA-binding experi-
ments. Gel mobility shift assay in Fig. 2A shows
the PRE-binding activities in the fractions from the
¢nal step of a⁄nity puri¢cation. Nearly all the TEF1
activity was retained by the DNA-a⁄nity column
(compare lanes 2 and 3). The TEF1 activity was
eluted in the 0.3 M, 0.4 M and 0.5 M KCl fractions,
with the 0.4 M fraction containing the most activity.
The eluted DNA-binding activity was con¢rmed to
be sequence-speci¢c to the PRE by competition ex-
periments using either speci¢c (PRE, lanes 7 and 10)
or nonspeci¢c (DRE, lanes 8 and 11) competitors.
Only a 7-fold excess of the unlabeled PRE was able
to completely inhibit TEF1^PRE interaction, indicat-
ing the high purity of the puri¢ed TEF1.
A silver-stained protein gel of the ¢nal fractions
was shown in Fig. 2B. The ¢nal TEF1 preparation
consists of one visible band with an apparent molec-
ular size of approximately 36 kDa. We could not rule
out the possibility that the ¢nal TEF1 preparation is
not in its full-sized natural form as the extensive
handling of the proteins during puri¢cation may re-
sult in the degradation of TEF1. However, our fur-
ther experiment demonstrated that this 36 kDa pro-
tein retained the transactivation activity on the
human TGF-K promoter (see below).
The observation that our ¢nal preparation consists
of only one major protein suggests that TEF1 is able
to bind to its speci¢c DNA sequence by itself, either
as a monomer or as a homopolymer. Results from
gel mobility shift assays (Fig. 2A) favor the notion
that TEF1 can form homopolymers on the DNA
because, besides the major shifted band, a second
and a very faint third shifted band appeared on the
gel that resembled the pattern of homo-multimeriza-
tion of proteins.
The puri¢cation e⁄ciency was summarized in Ta-
ble 1. Comparison of the total activity before and
after each step indicates that our DNA a⁄nity chro-
matography a¡ords a highly e⁄cient puri¢cation
step, recovering more than 35% of TEF1 from its
previous step. On the basis of protein^DNA binding
experiments, the overall recovery of TEF1 from rat
nuclear extract is about 15%. The total yield of TEF1
is V500 ng from 50 mg nuclear extracts. We there-
fore estimate that TEF1 consists of about 0.007% of
rat kidney nuclear proteins on the basis that TEF1
binds predominantly as monomer.
3.2. The puri¢ed 36 kDa protein is indeed the protein
that binds PRE
Gel mobility shift assay is a very sensitive method
in detecting protein^DNA interactions in that the
interacting protein at the picograms level can be de-
tected. This raises the possibility that the trace
amount of contaminating proteins that might remain
in the ¢nal preparation which were undetectable by
silver staining actually contributed to the shift in gel
mobility shift experiments. To determine whether the
protein corresponding to the 36 kDa major band on
the silver-stained gel is the TEF1 that speci¢cally
binds the PRE, UV cross-linking experiments using
puri¢cation fractions were performed (Fig. 3). Pro-
tein in the 0.4 M KCl fraction of DNA a⁄nity pu-
ri¢cation formed a covalent bond with the radiola-
Fig. 3. The 36 kDa protein is indeed TEF1. Protein fractions
obtained during the puri¢cation of TEF1 were incubated with
radiolabeled PRE and then UV irradiated for the indicated
times. Reactions in lanes 2 through 6 contained 3 Wl of the 0.4
M KCl fraction of the DNA a⁄nity puri¢cation, whereas reac-
tions in lanes 7 through 9 contained 3 Wl of the WGA chroma-
tography £ow-through fraction. Where indicated, a 35-fold ex-
cess of the speci¢c competitor (unlabeled PRE) was also added.
Molecular mass markers are indicated on the left. Reactions in
lanes 7 through 9 represent a separate UV irradiation experi-
ment with longer exposure time, thus the signal of the protein^
PRE complex appeared stronger relative to that of the 0.4 M
KCl fraction. Our other data (not shown) suggest that, when
an equal amount of the fractions was examined, the 0.4 M KCl
fraction gave stronger DNA-binding signal in both gel shift and
UV cross-linking experiments. UV, ultraviolet irradiation; FT,
£ow-through; +/3, with/without the corresponding reagent.
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beled PRE probe upon UV irradiation (lanes 3 to 6).
On a denaturing SDS^PAGE gel, this protein^DNA
complex migrated to about 36 kDa, consistent with
the molecular mass of the single visible band on the
silver-stained protein gel (Fig. 2B). Given the fact
that a small DNA fragment does not a¡ect signi¢-
cantly the mobility of the interacting protein, the
result shown here provides strong evidence that this
36 kDa protein is indeed TEF1. We also used the
£ow-through fraction of the WGA chromatography,
which is a relatively impure preparation, in the UV
cross-linking experiment. This fraction was able to
form a complex with the PRE at the same molecular
mass (lane 8), excluding the possibility that the inter-
action of PRE with the 36 kDa protein in the ¢nal
preparation was due to the predominant presence of
this protein. The interaction between the 36 kDa
protein with the PRE is sequence-speci¢c as the un-
labeled probe signi¢cantly blocked the formation of
the complex (lane 9).
3.3. Transcriptional activation of the TGF-K promoter
by puri¢ed TEF1
The results shown above demonstrated the ability
of the puri¢ed TEF1 to speci¢cally recognize its tar-
get sequence. However, it is also important to know
if the puri¢ed protein bears the function of a tran-
scriptional activator. Transcription assays were used
to analyze the function of TEF1. Because we do not
know at this stage if the expression of TEF1 is re-
stricted to certain tissues, we used HeLa nuclear ex-
tract as the source for RNA polymerase II and other
general transcription factors. As shown in Fig. 4, in
vitro transcription from the proximal TGF-K pro-
moter (3181 to +38, relative to the transcription
initiation site) was strongly activated by the addition
of the puri¢ed TEF1 in a dose-dependent manner
(left panel, lanes 2 and 3). The transactivation of
the promoter by TEF1 requires an intact PRE site
as a mutation in the PRE abolished activation by
TEF1 (right panel, lanes 3 and 4). These results pro-
vided evidence that the puri¢ed TEF1 possesses
transactivation activity on the TGF-K promoter
through its speci¢c interaction with the PRE. Inter-
estingly, a mutation at the neighboring AP-2 site
distal to the PRE also blocked transcriptional acti-
vation by TEF1 (right panel, lanes 5 and 6), implying
a possible functional cooperation between AP-2 and
TEF1. This potential cooperation, however, does not
seem to be dependent on the direct interaction be-
tween these two transcription factors, as suggested
by results from previous DNA^protein binding as-
says [31]. Here, we performed experiments to inves-
tigate other possible mechanisms of AP-2^TEF1 co-
operation (see below).
Fig. 4. Transcriptional activation by puri¢ed TEF1. (Left) Various amounts of the ¢nal TEF1 preparation (0.4 M KCl fraction from
the ¢nal puri¢cation step) were added to HeLa cell nuclear extract and examined for their ability to activate transcription from the
wild-type TGF-K promoter (3183 to +38) in an in vitro transcription assay. Transcription from the adenovirus major late promoter
(AdMLP) was also determined as an internal control for transcription e⁄ciency. Transcripts from di¡erent promoters are indicated
on the left. (Right) In vitro transcription assays were performed as described above, except that transactivation on the mutant TGF-K
promoter that contains a mutation at either the PRE (P220PREm) or the DRE (P220DREm) was also tested.
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3.4. Functional importance of PRE in vivo
To test the functional importance of PRE in vivo,
we transfected TGF-K promoter constructs into
MDA468 human mammary carcinoma cells (Fig.
5). Both the 220 bp (black bar) and the 1.1 kb
(shaded bar) TGF-K promoters were able to direct
e⁄cient transcription of the luciferase gene. How-
ever, when an 8 bp mutation was introduced into
the PRE, the promoter activity dropped signi¢cantly,
to about 40% of wild-type (PREm), whereas a con-
trol mutation 5P to the PRE (between PRE and
DRE) had no e¡ect. The observation that this muta-
tion had essentially the same e¡ect on the long 1.1 kb
promoter as it had on the 220 bp promoter provided
further support to our notion that PRE is an impor-
tant cis-element involved in TGF-K regulation in liv-
ing cells. The puri¢cation of TEF1 could help us
understand more about the mechanism of this regu-
lation.
3.5. The spacing between the AP-2 and the TEF1 sites
has little e¡ect on transcription from the TGF-K
promoter
In our attempt to understand the mechanism of
TEF1^AP-2 cooperation, we determined if the spac-
ing between the AP-2 and the TEF1 sites is impor-
tant for maintaining an e⁄cient level of TGF-K tran-
scription. Plasmid constructs containing various
spacing alignments of the AP-2 and the TEF1 sites
were transfected into MDA468 cells (Table 2). While
an 8 bp deletion of the spacing sequence induced a
moderate increase (1.6-fold) in luciferase activity,
other variations of the spacing (up to 96 bp insertion
of the exogenous sequence between the AP-2 and the
TEF1 sites) did not signi¢cantly a¡ect transcription
from the TGF-K promoter, indicating that the dis-
tance between the AP-2 and the TEF1 binding to the
DNA is not important in regulating TGF-K tran-
scription.
The helical orientation of cis-acting regulatory el-
ements is another factor that may a¡ect gene tran-
scription because it could in£uence direct or indirect
interaction between transcription factors bound to
these sites. DNA footprinting assay [31] indicates
that protein binding to the PRE is centered at
3101 of the TGF-K promoter, while protein binding
to the DRE is centered at 3112. Thus, AP-2 and
TEF1 appear to bind to the TGF-K promoter on
Fig. 5. Functional importance of PRE in vivo. Either the 220 bp
(black bars) or the 1.1 kb (shaded bars) TGF-K promoter frag-
ments were cloned upstream of the luciferase gene in the pGL2
plasmid and transfected into MDA468 human mammary carci-
noma cells. The PREm constructs contain a mutation within
the PRE (389 to 396, relative to the transcription initiation
site), whereas the control constructs contain a mutation outside
the PRE (3104 to 3111). Twenty Wg of each promoter^lucifer-
ase plasmid was transfected together with 10 Wg of the L-galac-
tosidase expression vector. Luciferase activities were normalized
to the L-galactosidase levels in the same cell lysate. Transfec-
tions were repeated three times, and variations of the luciferase
activities in percentage between each experiment were less than
10%.
Table 2
The spacing between AP-2 and TEF1 sites has little e¡ect on
transcription from the TGF-K promoter
Spacing construct DNA helical
turns
Transcription
activity
Wild-type N/A 1.00
8 bp Deletion 31 1.59 þ 0.33
16 bp Insertion (1U) +1.5 1.33 þ 0.15
32 bp Insertion (2U) +3 1.18 þ 0.32
64 bp Insertion (4U) +6.5 0.99 þ 0.08
96 bp Insertion (6U) +9.5 0.95 þ 0.11
TGF-K promoter spacing constructs were placed upstream of
the luciferase gene. Twenty Wg of each plasmid was transfected
into MDA 468 cells together with 10 Wg of the pCMV-Lgal, a
plasmid containing the CMV promoter-driving L-galactosidase
as a control for transcription e⁄ciency. Luciferase activities
were determined and normalized to the L-glactosidase activity
in the same lysate. The activity of the wild-type promoter is
standardized to 1.00. Changes in DNA helical orientations on
the two sites as a result of the alterations of spacing are also
indicated.
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the same side of the DNA helix. In this study, we
separated these two sites by an integral number of
helical turns, plus an additional half helical turn (the
1U, 4U, and 6U insertions). Though these changes
put the two sites on the opposite sides of the DNA
helix, transcription from these promoter constructs
remained essentially the same. This result is reminis-
cent of our previous ¢nding that the DRE- and the
PRE-binding proteins interact with their respective
sites in the TGF-K promoter independently and
they do not interact with each other upon binding
to the DNA [31]. The data here suggest that the
spacing and helical orientations between the AP-2
and the TEF1 sites have little or no e¡ect on tran-
scription from the TGF-K promoter.
4. Discussion
The expression of eukaryotic genes is tightly con-
trolled at the transcription level. Transcriptional reg-
ulation of genes is the basis of virtually every bio-
logical function of the eukaryotic cells. The
interaction between cis-acting DNA elements and
trans-acting transcription factors that recognize
such DNA elements is the major mechanism eukary-
otic cells employ to regulate transcription initiation
of their genes.
TGF-K is a growth factor important in both nor-
mal physiology and oncogenesis. The transcription of
the TGF-K gene is regulated under a variety of phys-
iological and pathological circumstances. TGF-K ex-
pression has been detected in various tissues during
normal development and in normal adults, including
pituitary, ovary, blood vessels, brain, and skin
[23,42^47]. In most of the tissues examined, TGF-K
expression appears to be con¢ned to speci¢c cell
types. TGF-K expression is also regulated in response
to metabolic and hormonal signals. In the mammary
cells, estrogen [21,48], phorbol esters [49], and EGF
(or TGF-K itself) [22^24] can regulate transcription
of this gene. Interestingly, TGF-K was ¢rst discov-
ered in tumor cells transformed by retroviruses or
spontaneously: these transformed cells expressed
this growth factor at higher levels than the parental
cell lines from which they were derived. TGF-K was
later found to be overexpressed in many types of
human cancers such as mammary, squamous, and
renal carcinomas, melanomas, hepatomas, and glio-
blastomas [5^7]. This observation of TGF-K overex-
pression in tumor cells gave rise to the autocrine
hypothesis, which was later con¢rmed by demon-
strating that TGF-K overexpression driven by heter-
ologous promoters in cell lines [8^10] or in transgenic
animals [11^14] results in the development of trans-
formed cells or tumors. Besides its implication in the
genesis and maintenance of tumors, TGF-K expres-
sion in arterial smooth muscle cells has been shown
to be induced by high glucose concentration (similar
to that in the diabetic patients) [18]. Elevated TGF-K
production may in turn stimulate the overprolifera-
tion of these cells, resulting in atherosclerosis in dia-
betic patients. That transcriptional activation of the
TGF-K gene can lead to marked phenotypic changes
prompted us to investigate the endogenous TGF-K
promoter.
TGF-K promoter has many features in common
with the promoters of housekeeping genes in that it
is GC-rich and does not contain a consensus TATA-
box. Like many housekeeping genes, transcription
from both the human [20] and rat [30] TGF-K pro-
moters is highly dependent upon the transcription
factor Sp1. The human TGF-K promoter also con-
tains an initiator element which is required for opti-
mal transcription and appears to direct transcription-
al initiation to a unique site in the TGF-K gene [29],
a feature not shared by other housekeeping genes
that do not contain an initiator element. The human
TGF-K promoter also contains a p53-responsive ele-
ment that may play a role in the repair of epithelial
damages caused by physical or chemical agents [28].
A nonconsensus TATA-box has also been de¢ned in
the human TGF-K gene whose position and sequence
is conserved in the rat gene and that contributes to
the transcriptional activity of the TGF-K promoter
[28]. More recently, an AP-2 element was de¢ned in
the proximal region of both human and rat TGF-K
promoters [31,32]. This element is essential for tran-
scription of this growth factor in cells derived from
various human cancers. A neighboring element
downstream from the AP-2 site, the PRE, is also
crucial in regulating the promoter activity. When
this element is mutated, the basal transcription
from the 1.1 kb TGF-K promoter decreased 60%
[31], indicating that this sequence is involved in the
control of the endogenous TGF-K expression. Our
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data also suggest that this element may cooperate
with its neighboring AP-2 element in the regulation
of the TGF-K promoter [31].
In this paper, we describe the puri¢cation and par-
tial characterization of the PRE-binding transcrip-
tion factor, TEF1. This protein was puri¢ed to ho-
mogeneity by sequence-speci¢c DNA a⁄nity
chromatography from rat kidney nuclear extracts.
The puri¢ed protein migrates as a single band with
a molecular mass of about 36 kDa. The size of the
puri¢ed TEF1 is in agreement with that estimated by
UV cross-linking experiments. On the basis of gel
mobility shift assays with the puri¢ed protein,
TEF1 is able to bind to its cognate site in homomul-
timers. Whether the homo-multimerization is neces-
sary for the binding or transactivation ability of
TEF1 remains to be elucidated.
To test the ability of TEF1 as a transcription acti-
vator, in vitro transcription assays using TGF-K pro-
moter templates containing either the wild-type or
the mutant PRE were performed. Transcription
from the proximal TGF-K promoter was strongly
activated by the addition of the puri¢ed TEF1.
This activation of transcription depended on an in-
tact PRE site because TEF1 failed to activate tran-
scription from the promoter containing a mutation
at the PRE. These results, together with our transient
transfection data that the PRE is essential for tran-
scription directed by the 1.1 kb TGF-K promoter,
strongly indicate the functional importance of the
PRE element in living cells. Interestingly, in in vitro
study, TEF1 also failed to enhance TGF-K transcrip-
tion from the promoter that contained a wild-type
PRE and a mutant neighboring AP-2 element, sug-
gesting that TEF1 cooperates with AP-2 in the con-
trol of TGF-K transcription. This is in agreement
with our previous results which suggest that both
the AP-2 and TEF1 elements are necessary for the
transcriptional activity of a larger element, the TKRE
I, that contains both the AP-2 element and PRE [31].
Other studies on transcriptional regulation by AP-2
have suggested that AP-2 cooperates with other tran-
scription factors in mediating transcriptional activa-
tion in response to signals induced by the develop-
mental morphogen retinoic acid [50,51], and to the
signals mediated through the activation of cAMP-
dependent protein kinase and protein kinase C [52^
54]. In the case of the keratin K14 promoter, AP-2
appears to play a role in the tissue-speci¢c expression
of K14 in keratinocytes but it does so in cooperation
with a neighboring element [55]. We have done a
preliminary study on the possible cooperation be-
tween AP-2 and TEF1. To determine whether the
spacing between the AP-2 and TEF1 elements is cru-
cial for TGF-K transcription, we have either inserted
or deleted DNA sequences of various lengths be-
tween the AP-2 and TEF1 elements, resulting in ei-
ther a full or half helical turn of either of the two
elements away from the other. However, no signi¢-
cant variations in transcription from the TGF-K pro-
moter have been detected. We also know that direct
protein^protein interaction between AP-2 and TEF1
upon their binding to their respective sites does not
exist, at least in our experimental system [31]. If and
how these two factors cooperate with each other in
regulating the TGF-K promoter activity awaits fur-
ther investigation. Other mechanisms that may ex-
plain AP-2 and TEF1 cooperation include the fol-
lowing: (i) AP-2 and TEF1 interact with the basal
transcription machinery in an independent but coor-
dinated manner; and (ii) binding of either AP-2 or
TEF1 to the DNA opens up the DNA structure that
makes the other site more accessible to transcription
factor binding. Also interesting to know is the tissue
speci¢city of TEF1 and how its expression and func-
tion are controlled by upstream signaling events.
Getting the answers to these questions could be
greatly facilitated by cloning the gene for TEF1.
The puri¢cation of this transcription factor is an im-
portant step to achieve this goal.
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